ABSTRACT
INTRODUCTION
According to a national screening policy introduced in 2004, all pregnant women in Denmark are offered a publicly funded combined first-trimester screening test (cFTS) for aneuploidy (based on maternal age, nuchal translucency (NT) thickness and maternal serum pregnancy-associated plasma protein-A and β-human chorionic gonadotropin levels) and a fetal anomaly scan at 18-20 weeks' gestation 1, 2 . Ninety-three percent of pregnant Danish women attend cFTS and 96% undergo an anomaly scan through this program 3 . Since September 2015, pregnancies with an increased risk for aneuploidy (trisomy 21 risk ≥ 1:300 or trisomy 13/18 risk ≥ 1:150) have been offered invasive or non-invasive (NIPT) prenatal testing. The laboratory analyzing samples of prenatal tests for patients living within the central and northern regions of Denmark now also provides a molecular karyotype based on chromosomal microarray (CMA) analysis.
Although the cFTS program was designed to detect pregnancies affected by trisomies 21, 18 and 13, it also has good sensitivity for a broad range of atypical chromosomal abnormalities 4 . Rare genetic syndromes, caused by submicroscopic chromosomal imbalances, are often not detectable by ultrasound and have traditionally been missed using conventional cytogenetic techniques; however, they are detectable by CMA. CMA has significant advantages over chromosome analysis, not only in the postnatal setting but also prenatally, and has been adopted as the preferred genomic test for fetuses with structural malformations [5] [6] [7] [8] . We have shown previously that the prevalence of atypical abnormal karyotypes is increased significantly in fetuses with increased NT 9 . We report the performance of CMA as the primary diagnostic genomic test for women with a high risk for aneuploidy on population-based cFTS screening. The impact of changing cFTS risk cut-offs that have been proposed for contingent screening models offering NIPT to women with a cFTS risk > 1 in 50 was also reviewed.
METHODS
This was a retrospective cohort study evaluating the genomic findings of consecutive pregnancies that had invasive testing after receiving a cFTS result indicating increased risk for trisomies 21, 18 or 13. The study included all samples obtained for invasive testing from pregnancies managed by the Clinical Genetics Service for the central and northern regions of Denmark, between 1 st September 2015 and 12 th September 2016. Samples analyzed for other clinical indications, such as ultrasound-detected structural abnormalities, increased NT (≥ 3.5 mm) and intrauterine growth restriction (IUGR; biometry > 2 SDs from mean), recognized previously as having an association with submicroscopic chromosomal abnormalities, were excluded, as an increased detection rate of CMA has already been documented for these groups. Publication of de-identified case series is exempt from institutional review board review in Denmark.
The basis of the cFTS screening program has been reported previously 1, 2 ; it includes sonographic assessment at 11 + 2 to 13 + 6 weeks' gestation by sonographers and doctors certified by The Fetal Medicine Foundation, London, UK. Women at high risk for trisomy 21 (≥ 1 in 300) or for trisomies 18/13 (≥ 1 in 150) were counseled regarding options for further testing. These options included a NIPT test (NIPT analysis was based on low coverage whole-genome sequencing of maternal plasma DNA, restricted to screening for trisomies 21, 18 and 13 and sex chromosomes) or an invasive test (chorionic villus sampling (CVS) or amniocentesis with analysis by CMA). Women were counseled on the relative advantages and disadvantages of these two approaches, including risk of miscarriage and identification of variants of unknown significance (VOUS) in invasive testing and the risk of missing atypical chromosomal aberrations on NIPT. Our laboratory does not serve the region of Northern Denmark for NIPT, therefore NIPT data are only available for the Central Denmark region. During the study period, 242 NIPT and 512 CMA analyses were performed for pregnancies with a risk ≥ 1:300 in the Central Denmark region. The NIPT and CMA groups had an even aneuploidy distribution. Of the 575 CMA samples included in this study, 512 came from the Central Denmark region.
CVS samples were dissected microscopically to remove any contaminating maternal decidua, and amniotic fluid samples were inspected for contamination with maternal blood prior to DNA extraction. DNA was extracted immediately from uncultured samples using the Maxwell 16 LEV Blood DNA kit (Promega, Madison, WI, USA). For CMA analysis, all samples were screened using the SurePrint G3 Human CGH microarray 180 K (Agilent Technologies Inc., Santa Clara, CA, USA). Sample and reference genomic DNA (500 ng) were labeled with Cy5 (reference) or Cy3 (specimen) using the SureTag Complete DNA labeling Kit (Agilent Technologies Inc.), and purified as per the manufacturer's protocol. Labeled sample and reference DNA were pooled and 5 μL human COT-1 DNA (1 mg/mL), 10× blocking agent, and 2× hybridization buffer were added. Hybridization lasted 20-24 hr at 67
• C. Scanning and image acquisition were carried out using an Agilent microarray scanner, and quantification of microarray image files and data analysis were performed using CytoGenomics version 3.0.6.6 (Agilent Technologies Inc.). Copy number was determined using the adm-2 algorithm, and profile deviations consisting of four or more neighboring oligonucleotides were considered genomic aberrations. Thus, the resolution was approximately 50 kb. Copy-number gains or losses were compared with our in-house database of copy number variants (CNVs) and with public CNV databases (Database of Genomic Variants: http:// http://dgv.tcag.ca/dgv/app/home; Decipher: http://decipher.sanger.ac.uk/; ClinGen: https://www .clinicalgenome.org/). If abnormal copy number changes of unknown clinical significance were detected in the CVS/amniotic fluid sample, parental samples were analyzed for the aberration.
CNVs were categorized as benign, pathogenic or VOUS, based on Miller et al. 10 and the American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional CNVs 11 . A subgroup of the pathogenic CNVs was additionally labeled 'susceptibility variant' according to Rosenfeld et al. 12, 13 . Chi-square and McNemar two-tailed tests were used for statistical analysis and http://vassarstats.net/ was used for the calculation of CIs.
RESULTS
A consecutive cohort of 575 pregnancies underwent invasive testing on the basis of an increased risk on cFTS screening. The cohort included 139 (24.2%) pregnancies with a risk > 1 in 50, 135 (23.5%) with a risk between 1 in 50 and 1 in 99 and 301 (52.3%) with a risk between 1 in 100 and 1 in 300. Median maternal age was 33 years (range, 21-47 years). 561 women had CVS and 14 amniocentesis. Primary CMA results were available in all cases within 7 days of invasive testing. Follow-up analyses (parental samples) increased reporting times by up to 5 days.
CMA revealed an abnormal result (aneuploidy, pathogenic or probably pathogenic CNVs) in 51/575 (8.9% (95% CI, 6.8-11.5%)) of pregnancies (Table 1) . These included 22 (3.8% (95% CI, 2.5-5.7%)) cases with common trisomies (21, 18 and 13) and six (1.0% (95% CI, 0.5-2.3%)) with sex chromosome aneuploidy. Trisomies of chromosomes other than 21, 18 and 13 were detected in eight (1.4 % (95% CI, 0.7-2.7%)) cases (Table 1) .
In addition, CMA detected pathogenic deletions or duplications in 13 cases (2.3% (95% CI, 1.3-3.8%)), and a probable pathogenic CNV was reported in an additional two cases (0.3% (95% CI, 0.0-1.2%)). The complete list of detected deletions and duplications is summarized in Table 2 . Of the 15 CNVs, three were > 10 Mb in size and would probably have been detected by chromosomal analysis; however, the other 12 CNVs would most probably not have been detected using conventional cytogenetic techniques. The overall detection rate for CMA (51/575; 8.9% (95% CI, 6.8-11.5%)) was therefore significantly higher than that estimated for conventional cytogenetic analysis (39/575; 6.8% (95% CI, 5.0-9.1%)) (P = 0.0049, McNemar two-tailed test).
Susceptibility variants
Six of the 13 pathogenic deletions/duplications detected by CMA had decreased penetrance and we named this subgroup of pathogenic CNVs as susceptibility variants (16p11.2 duplication, 16p12.1 deletion, 17q12 duplication and 22q11.2 duplication). In five of these cases, the aberration was maternally inherited. One aberration was a de-novo 22q11.1 duplication. Excluding these susceptibility variants (n = 6) the detection rate by CMA would be 45/575 (7.8% (95 CI, 5.9-9.3%)), which is also significantly higher than the estimated detection rate on conventional cytogenetic analysis (39/575; P = 0.03, McNemar two-tailed test).
VOUS and benign CNVs
In one case, with a cFTS risk of 1 in 295, a de-novo VOUS was detected (Table 2 ). In two cases (cFTS risks 1 in 193 and 1 in 256) maternally inherited 15q11.2 deletions, BP1-BP2 (OMIM 615656) were detected and these findings were categorized as probably benign, but were reported to the patients.
In 11 (1.9% (95% CI, 1.1-3.4%)) of the 575 cases, CMA detected one or more genomic aberrations not reported previously in the publicly available variant databases (data not shown). These variants were all found to be inherited from a healthy parent and were categorized as benign, but were not reported to the patients. In all cases in which analysis of parental samples was necessary for evaluation of clinical significance, we were able to retrieve, analyze and interpret both parental samples.
Incidental findings
An incidental finding was considered a finding with potential health implications unknown to the pregnant couple, which was discovered unexpectedly and was unrelated to the purpose, and beyond the aim, of the prenatal analysis (for example, the detection of a pathogenic deletion in the DM1-gene in a female fetus). Incidental findings were identified in four cases (0.7 % (95% CI, 0.3-1.8%)). These consisted of a maternally inherited 0.6-Mb deletion involving the MSX2 gene, which is associated with enlarged parietal foramina type 1, two cases of maternally inherited 0.9-Mb deletion involving the SHOX gene, which is associated with Léri-Weill dyschondrosteosis and a 0.6-Mb deletion on chromosome Yq involving the RBMY2EP gene, which is associated with azoospermia/oligospermia.
Unusual aneuploidies and mosaicism
Mosaicism of any kind was detected in 18 (3.2% (95% CI, 2.0-5.0%)) cases of CVS (n = 562). These included three cases with common aneuploidies, six cases with sex chromosome abnormalities, six aneuploidies other than trisomies 21, 18 and 13 and three cases with other chromosomal abnormalities.
Trisomy of chromosomes other than 21, 18 and 13 was detected in eight cases (1.4% (95% CI, 0.7-2.7%)) of CVS (Table 1) . A non-mosaic trisomy was detected in two of these cases (chromosomes 5 and 9, respectively); in both cases, an anomaly scan at 15-16 weeks' gestation showed structural abnormalities not visible at cFTS, and the pregnancies were terminated without further follow-up. The other six aneuploid cases included two cases of mosaic trisomy for chromosome 7, one each of mosaic trisomy for chromosomes 9, 12 and 20, and one case of mosaicism for both chromosomes 7 and 16. Four of the six mosaic cases had no trisomy in a follow-up amniotic fluid sample and in two cases (chromosomes 7 and 20) no further analysis on amniotic fluid or fetal tissue was carried out. No case of mosaicism was detected among the 14 amniotic fluid samples.
Genomic outcomes in relation to cFTS findings
The prevalence of common trisomies (21, 18 and 13) was, as expected, significantly higher (18/139; 12.9% Data are reported as n (%). For each category of abnormal findings, data in square brackets are percentages calculated against total number of such findings in whole cohort. *Number of pathogenic copy number variants (CNVs) that are syndromes with variable phenotypic effects that do not always result in severe impairment and may be inherited from a parent with minimal or no clinical features such as 22q11 duplication syndrome 12 . All above findings were reported to patients, including two probably benign CNVs: 15q11 BP1-BP2 deletion. SCA, sex chromosome aneuploidy; VOUS, variants of unknown significance.
(95% CI, 8.4-19.5%)) among women with a cFTS risk > 1 in 50 than among women with a cFTS risk between 1 in 100 and 1 in 300 (3/301; 1.0% (95% CI, 0.3-2.9%)), (chi-square 2×3, P < 0.001). Conversely, the prevalence of pathogenic CNVs was highest among pregnancies with a cFTS risk between 1 in 100 and 1 in 300 (8/301; 2.7% (95% CI, 1.4-5.2%)) and lowest in the group with a risk > 1 in 50 (0/139; 0% (95% CI, 0-2.7%)) (chi-square 2×3, not significant).
DISCUSSION
In this clinical series of pregnancies with increased risk on cFTS, CMA detected abnormal results in 8.9% of pregnancies. Fewer than half of the abnormal findings (23/51) were detected in pregnancies in the group with the highest risk (> 1 in 50), and a substantial number of abnormal findings were detected in the groups with risk 1:50 to 1:100 (n = 12) and 1:100 to 1:300 (n = 16). Of the 28 abnormal results in pregnancies with a risk between 1 in 50 and 1 in 300, only four could have been detected by NIPT focused on chromosomes 21, 18 and 13.
The cFTS algorithm is designed to detect trisomies 21, 18 and 13 and, not surprisingly, we found the highest proportion of these trisomies among the women with a risk of > 1 in 50 (18/139). The risk algorithm also identifies a significant proportion of other chromosomal abnormalities, including a range of pathogenic CNVs -although this was not the primary intention. Some centers 14 now offer NIPT rather than karyotyping to women identified as being at high risk for chromosomal abnormalities, or they follow a contingent strategy offering NIPT to women with a cFTS risk between 1 in 50 and 1 in 1000 and invasive testing to those with a cFTS risk > 1 in 50. If a contingent strategy (CMA for risk above 1 in 50 and NIPT for risk between 1 in 50 and 1 in 1000) had been applied here, then 24/51 abnormal results (four sex chromosome aberrations, six other aneuploidies and 14 CNVs) would have been overlooked.
This study confirms that, in comparison with traditional cytogenetic techniques, the use of CMA increases the detection rate of chromosomal abnormalities. The overall yield was 8.9% compared with 6.8%, defined by those aneuploidies or CNVs above 10 Mb that probably would have been detected by cytogenetic analysis. Categorization of susceptibility variants is controversial and some clinicians consider them to be an incidental, or even unwanted, result, but the diagnostic yield of CMA would have increased significantly even if they had been excluded. The value of using CMA compared with cytogenetic analysis or NIPT when assessing fetuses with structural malformations [5] [6] [7] [8] 16 estimated the probability of a pathogenic CNV to be 0.7%, with an additional 1.4% probability of finding a susceptibility variant. Few studies describe the probability of finding a pathogenic CNV, including susceptibility variants, in the general population. Population rates of 0.4-1.7% 8, 17, 18 have been suggested, but these cases were typically selected based on parameters included in the trisomy risk assessment, such as advanced maternal age, increased NT or divergent biochemical parameters. The 'true' risk of pathogenic CNV in an unselected low-risk population might therefore be lower.
When NIPT was first introduced, clinical guidelines suggested that it should be used for women defined as being at high risk through traditional screening tests, including women with a cFTS risk ≥ 1:300 [19] [20] [21] . NIPT is 12 . CNV, copy number variant; del, deletion; dup, duplication; ISCN, International System for Human Cytogenetic Nomenclature, in which karyotyping is based on hg19 assembly; LFU, lost to follow-up; OMIM, Online Mendelian Inheritance in Man; TOP, termination of pregnancy; VOUS, variants of uncertain significance. now cheaper than invasive testing and sample collection requires less technical expertise. Consequently, some centers promote NIPT as an alternative to invasive testing. The present study shows that, if NIPT is used as an alternative to invasive testing, there is a substantial risk that a pathogenic CNV will be missed, or identified only later in pregnancy. We believe it is important that this information is included in pretest counseling, especially as, in many cases, the absolute risk of identifying a pathogenic CNV is substantially higher than the defined risk for trisomy 21, the initial indication for invasive testing.
The extent to which findings from prenatal CMA should be reported continues to be a subject of debate 22, 23 . Our policy, after discussion and obtaining consent, is to report all findings to the pregnant woman including susceptibility variants, even though these do not have full penetrance. An example of this is the finding of 22q11 duplication syndrome, which carries a penetrance of 22% 12 . We have adopted this approach in order to respect the patient's autonomy; in our experience, a risk may be perceived differently based on the cumulative experience of a family. Furthermore, we believe that these cases should be handled with greater care and additional ultrasound assessments, as these susceptibility variants carry an increased risk of malformations and impairments 8, 12, 24 . In six cases, we detected such susceptibility variants that may result in impairments and malformations, but that are commonly inherited from a parent with minimal or no clinical features. Prenatal counseling in these cases is difficult and, at our hospital, is often carried out by a clinical geneticist and a fetal medicine expert in a combined session 25 . It is our experience that, when this session is initiated with review of the family history, it is not uncommon to discover pre-existing knowledge of these variants in the family and also to learn the vocabulary the family have previously used to describe this. This facilitates a sharing of uncertain results and democratizes the counseling session 26, 27 . In four of the five cases reported in this series, the CNV was maternally inherited and all these pregnancies continued.
In the present series, mosaicism was detected in 3.2% (95% CI, 2.0-5.0%) of CVS samples from high-risk pregnancies. Chromosomal mosaicism is detected in 1-3% of CVS specimens after standard chromosome analysis 28, 29 . We use direct DNA preparations from undigested villi to ensure maximum detection rates of potential mosaicism from both mesenchymal core and cytotrophoblast cells, and follow up with amniocentesis in cases of mosaicism. We think that identification of these pregnancies is important owing to the risk of fetal aneuploidy, but also because of the risk of growth restriction, even in cases in which subsequent amniocentesis does not detect the aberration 30, 31 . Identification of these pregnancies for additional surveillance can reduce the risk of IUGR-related adverse outcomes [30] [31] [32] . In conclusion, this study has demonstrated that high-resolution CMA can diagnose accurately a significant number of chromosomal aberrations in pregnancies with increased risk for aneuploidy on cFTS. The distribution of aneuploidies and CNVs was uneven, with a higher prevalence of 'traditional' aneuploidies seen in cases with a cFTS risk of > 1 in 50, while pathogenic CNVs were more prevalent in the group with a risk between 1 in 100 and 1 in 300. Limiting diagnostic testing to pregnancies with a risk above 1 in 100 or 1 in 50, as proposed in contingent NIPT/invasive testing models, would lead to a significant proportion of pathogenic CNVs being missed on first-trimester screening. If contingent screening is to be introduced, women need to be informed of this risk so that they can make an informed choice between NIPT and invasive testing.
